title: Effects of interleukin 2 therapy in patients with common variable immunodeficiency (CVID).
authors.affiliation: Dept. of Rheumatology, University of Freiburg, FRG.
authors.forename: J A
authors.initials: JA
authors.lastname: Rump
authors.forename: A
authors.initials: A
authors.lastname: Jahreis
authors.forename: M
authors.initials: M
authors.lastname: Schlesier
authors.forename: S
authors.initials: S
authors.lastname: Stecher
authors.forename: R
authors.initials: R
authors.lastname: Dräger
authors.forename: W G
authors.initials: WG
authors.lastname: Struff
authors.forename: H H
authors.initials: HH
authors.lastname: Peter
mesh_terms: D017074:Common Variable Immunodeficiency / Q000145:classification / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000494:pharmacology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013745:Tetanus Toxoid / Q000494:pharmacology
chemical_list: D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D007376:Interleukin-2; D016853:Muromonab-CD3; D011043:Pokeweed Mitogens; D015375:Receptors, Interleukin-2; D013745:Tetanus Toxoid